Skip to content

PEPENDIUM LABS

Free research / Saved source records

Saved studies for Tirzepatide

This collection contains studies found in earlier source checks. Historical collection checks Europe PMC and ClinicalTrials.gov; live search also checks PubMed when available. The collection can include older work beyond live search windows, but is not a complete archive. Source metadata may have changed since the last check. See collection progress.

Historical scan for Tirzepatide

3 year/page windows checked · Last completed: Mon, 28 Sep 2026 21:15:58 GMT · Next: 2026, page 4 · A source check failed; retry pending.

This progress applies to the tracked spelling shown above. It does not measure every study or every source.

43 saved studies linked to this search · Page 2

Original study · Category hint: Human · Published: 2026-04-21

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗

Original analysis · Category hint: Economic model · Published: 2026-03-02

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗

Original study · Category hint: Human · Published: 2023 Apr

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗View at PubMed ↗

Original analysis · Category hint: Economic model · Published: 2022-12-27

Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗View at PubMed ↗

Original study · Category hint: Other or unclear · Published: 2022-12-06

Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗View at PubMed ↗

Original study · Category hint: Human · Published: 2022-11-02

Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗View at PubMed ↗

Original study · Category hint: Animal · Published: 2022-09-12

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.

Last found in a complete check: Sep 28, 2026

View at Europe PMC ↗View at PubMed ↗

Trial results posted · Category hint: Human · Results posted: 2022-04-14

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Trial results posted · Category hint: Human · Results posted: 2022-02-14

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Trial results posted · Category hint: Human · Results posted: 2022-02-14

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Trial results posted · Category hint: Human · Results posted: 2022-02-14

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Trial results posted · Category hint: Human · Results posted: 2022-01-19

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Trial results posted · Category hint: Human · Results posted: 2022-01-12

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Last found in a complete check: Sep 28, 2026

View at ClinicalTrials.gov ↗

Original study · Category hint: Human · Published: 2022 Sep

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.

Last found in a complete check: Sep 28, 2026

View at PubMed ↗

Original study · Category hint: Human · Published: 2022 Sep

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.

Last found in a complete check: Sep 28, 2026

View at PubMed ↗

Original study · Category hint: Human · Published: 2022 Nov

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

Last found in a complete check: Sep 28, 2026

View at PubMed ↗

Original study · Category hint: Human · Published: 2022 Aug 24

[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].

Last found in a complete check: Sep 28, 2026

View at PubMed ↗

Original study · Category hint: Human · Published: 2022 Aug

Tirzepatide to treat obesity: phase III results.

Last found in a complete check: Sep 28, 2026

View at PubMed ↗

Check live sources for Tirzepatide →